个性化医疗中的卫生技术评估：成本效益分析实例 - Suppr

Suppr

超能文献

Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis.

作者信息

Postma Maarten J, Boersma Cornelis, Vandijck Dominique, Vegter Stefan, Le Hoa H, Annemans Lieven

出版信息

Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):367-9. doi: 10.1586/erp.11.50.

DOI:10.1586/erp.11.50

PMID:21831013

Abstract

摘要

相似文献

Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis.

Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):367-9. doi: 10.1586/erp.11.50.

Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcare.

Expert Rev Pharmacoecon Outcomes Res. 2016 Aug;16(4):435-7. doi: 10.1080/14737167.2016.1180980. Epub 2016 May 6.

Technology assessment: approach and reimbursement.

Spine (Phila Pa 1976). 2007 May 15;32(11 Suppl):S39-43. doi: 10.1097/BRS.0b013e318054d0a0.

Personalized medicine policy challenges: measuring clinical utility at point of care.

Expert Rev Pharmacoecon Outcomes Res. 2012 Jun;12(3):289-95. doi: 10.1586/erp.12.15.

Procedures and methods of benefit assessments for medicines in Germany.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study.

Value Health. 2011 Jun;14(4):608-15. doi: 10.1016/j.jval.2010.11.011.

Technology assessment for new oncology drugs.

Clin Cancer Res. 2013 Jan 1;19(1):6-11. doi: 10.1158/1078-0432.CCR-12-1819.

[New EBM: is it really so detrimental to physicians?].

MMW Fortschr Med. 2004 Sep 23;146(39):56-7.

[Haute Autorite de sante opinion on cost-effectiveness of health products : results and perspectives].

Sante Publique. 2015 Sep-Oct;27(5):691-700.

Better defining target populations for drugs with a view to reimbursement.

Therapie. 2014 May-Jun;69(3):235-7. doi: 10.2515/therapie/2014027. Epub 2014 Jun 16.

引用本文的文献

Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration.

Eur J Health Econ. 2019 Apr;20(3):475-482. doi: 10.1007/s10198-018-1013-z. Epub 2018 Oct 29.

Economic evaluation of personalized medicine: a call for real-world data.

Eur J Health Econ. 2017 Dec;18(9):1065-1067. doi: 10.1007/s10198-017-0890-x.

Implementing personalized medicine with asymmetric information on prevalence rates.

Health Econ Rev. 2016 Dec;6(1):35. doi: 10.1186/s13561-016-0113-7. Epub 2016 Aug 18.

Some economics on personalized and predictive medicine.

Eur J Health Econ. 2015 Dec;16(9):985-94. doi: 10.1007/s10198-014-0647-8. Epub 2014 Nov 8.

Stratified medicine and reimbursement issues.

Front Pharmacol. 2012 Oct 15;3:181. doi: 10.3389/fphar.2012.00181. eCollection 2012.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis.

Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):367-9. doi: 10.1586/erp.11.50.

Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcare.

Expert Rev Pharmacoecon Outcomes Res. 2016 Aug;16(4):435-7. doi: 10.1080/14737167.2016.1180980. Epub 2016 May 6.

Technology assessment: approach and reimbursement.

Spine (Phila Pa 1976). 2007 May 15;32(11 Suppl):S39-43. doi: 10.1097/BRS.0b013e318054d0a0.

Personalized medicine policy challenges: measuring clinical utility at point of care.

Expert Rev Pharmacoecon Outcomes Res. 2012 Jun;12(3):289-95. doi: 10.1586/erp.12.15.

Procedures and methods of benefit assessments for medicines in Germany.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study.

Value Health. 2011 Jun;14(4):608-15. doi: 10.1016/j.jval.2010.11.011.

Technology assessment for new oncology drugs.

Clin Cancer Res. 2013 Jan 1;19(1):6-11. doi: 10.1158/1078-0432.CCR-12-1819.

[New EBM: is it really so detrimental to physicians?].

MMW Fortschr Med. 2004 Sep 23;146(39):56-7.

[Haute Autorite de sante opinion on cost-effectiveness of health products : results and perspectives].

Sante Publique. 2015 Sep-Oct;27(5):691-700.

Better defining target populations for drugs with a view to reimbursement.

Therapie. 2014 May-Jun;69(3):235-7. doi: 10.2515/therapie/2014027. Epub 2014 Jun 16.

引用本文的文献

Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration.

Eur J Health Econ. 2019 Apr;20(3):475-482. doi: 10.1007/s10198-018-1013-z. Epub 2018 Oct 29.

Economic evaluation of personalized medicine: a call for real-world data.

Eur J Health Econ. 2017 Dec;18(9):1065-1067. doi: 10.1007/s10198-017-0890-x.

Implementing personalized medicine with asymmetric information on prevalence rates.

Health Econ Rev. 2016 Dec;6(1):35. doi: 10.1186/s13561-016-0113-7. Epub 2016 Aug 18.

Some economics on personalized and predictive medicine.

Eur J Health Econ. 2015 Dec;16(9):985-94. doi: 10.1007/s10198-014-0647-8. Epub 2014 Nov 8.

Stratified medicine and reimbursement issues.

Front Pharmacol. 2012 Oct 15;3:181. doi: 10.3389/fphar.2012.00181. eCollection 2012.